Pharmacy
Feb 21, 2023
The market for biosimilar drugs to treat cancer, inflammatory diseases, diabetes and more will continue to expand, ideally resulting in lower prices as more pharmaceutical patents expire and competitors enter the market.
Feb 10, 2023
The Food and Drug Administration yesterday revised its recent guidance for outsourcing facilities compounding certain ibuprofen oral suspension products.
Nov 18, 2022
Hosted by the American Hospital Association in partnership with McKesson
Join your hospital and health system executive peers in a virtual discussion to explore the barriers you face to streamline operational and access challenges to improve affordability and patient care excellence. …
Nov 15, 2022
In 2023, provider organizations can expect significant evolutionary changes in how to optimize patient engagement, the ever-expanding role that retail clinics will play in care delivery and some upheaval in venture capital funding for health care startups.
Oct 13, 2022
The market for pharmacy benefit manager services is highly concentrated, with commercial insurers often sharing ownership in the PBM, according to the analysis.
Jun 7, 2022
The FTC will launch an inquiry into the prescription drug middleman industry.
May 24, 2022
Increases in consolidation and alignment between commercial health plans and pharmacy benefit managers have resulted in a series of business practices designed to steer patients to insurer-affiliated pharmacies and away from patients’ longstanding providers to the detriment of patient care.
May 24, 2022
The AHA urges the FTC to increase scrutiny on insurer-mandated white bagging policies, as well as the impact of PBM-negotiated rebates and other business practices on the 340B drug discount pricing program and overall drug prices and drug price increases.
Oct 6, 2021
As recommended by the AHA, the Food and Drug Administration proposed revising 2016 draft guidance to allow hospital and health system pharmacies that are not outsourcing facilities to distribute compounded drug products to any health care facility in the same system without first receiving a valid…
Jul 9, 2021
Fourteen leading U.S. drug companies from 2016 to 2020 spent $577 billion on stock buybacks and dividends, $56 billion more than they spent on research and development over the same period, according to a report released by the House Committee on Oversight and Reform.